Magnetic resonance imaging of ethyl-nitrosourea-induced rat gliomas: A model for experimental therapeutics of low-grade gliomas

P. E. Kish, M. Blaivas, M. Strawderman, K. M. Muraszko, Donald (Don) Ross, B. D. Ross, G. McMahon

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Human low-grade gliomas represent a population of brain tumors that remain a therapeutic challenge. Preclinical evaluation of agents, to test their preventive or therapeutic efficacy in these tumors, requires the use of animal models. Spontaneous gliomas develop in models of chemically induced carcinogenesis, such as in the transplacental N-ethyl-N-nitrosourea (ENU) rat model. However, without the ability to detect initial tumor formation, multiplicity or to measure growth rates, it is difficult to test compounds for their interventional or preventional capabilities. In this study Fisher-334 rats, treated transplacentally with ENU, underwent magnetic resonance imaging (MRI) examination in order to evaluate this approach for detection of tumor formation and growth. ENU-induced intracranial cerebral tumors were first observable in T2-weighted images beginning at 4 months of age and grew with a mean doubling time of 0.487 ± 0.112 months. These tumors were found histologically to be predominately mixed gliomas. Two therapeutic interventions were evaluated using MRI, vitamin A (all-trans retinol palmitate, RP), as a chemopreventative agent and the anti-angiogenic drug SU-5416. RP was found to significantly delay the time to first tumor observation by one month (P = 0.05). No differences in rates of tumor formation or growth rates were observed between control and RP-treated groups. MRI studies of rats treated with SU-5416 resulted in reduction in tumor growth rates compared to matched controls. These results show that MRI can be used to provide novel information relating to the therapeutic efficacy of agents against the ENU-induced tumor model.

Original languageEnglish (US)
Pages (from-to)243-257
Number of pages15
JournalJournal of Neuro-Oncology
Volume53
Issue number3
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Glioma
Theoretical Models
Magnetic Resonance Imaging
Ethylnitrosourea
Neoplasms
Therapeutics
Growth
Vitamin A
Angiogenesis Inhibitors
Brain Neoplasms
Carcinogenesis
Animal Models
Observation
Population
retinol palmitate

Keywords

  • ENU
  • Gliomas
  • Magnetic resonance imaging
  • N-ethyl-N-nitro sourea
  • Transplacental induction

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neuroscience(all)

Cite this

Magnetic resonance imaging of ethyl-nitrosourea-induced rat gliomas : A model for experimental therapeutics of low-grade gliomas. / Kish, P. E.; Blaivas, M.; Strawderman, M.; Muraszko, K. M.; Ross, Donald (Don); Ross, B. D.; McMahon, G.

In: Journal of Neuro-Oncology, Vol. 53, No. 3, 2001, p. 243-257.

Research output: Contribution to journalArticle

Kish, P. E. ; Blaivas, M. ; Strawderman, M. ; Muraszko, K. M. ; Ross, Donald (Don) ; Ross, B. D. ; McMahon, G. / Magnetic resonance imaging of ethyl-nitrosourea-induced rat gliomas : A model for experimental therapeutics of low-grade gliomas. In: Journal of Neuro-Oncology. 2001 ; Vol. 53, No. 3. pp. 243-257.
@article{f8e8a91913bb4d88b6b7bca733fdf4eb,
title = "Magnetic resonance imaging of ethyl-nitrosourea-induced rat gliomas: A model for experimental therapeutics of low-grade gliomas",
abstract = "Human low-grade gliomas represent a population of brain tumors that remain a therapeutic challenge. Preclinical evaluation of agents, to test their preventive or therapeutic efficacy in these tumors, requires the use of animal models. Spontaneous gliomas develop in models of chemically induced carcinogenesis, such as in the transplacental N-ethyl-N-nitrosourea (ENU) rat model. However, without the ability to detect initial tumor formation, multiplicity or to measure growth rates, it is difficult to test compounds for their interventional or preventional capabilities. In this study Fisher-334 rats, treated transplacentally with ENU, underwent magnetic resonance imaging (MRI) examination in order to evaluate this approach for detection of tumor formation and growth. ENU-induced intracranial cerebral tumors were first observable in T2-weighted images beginning at 4 months of age and grew with a mean doubling time of 0.487 ± 0.112 months. These tumors were found histologically to be predominately mixed gliomas. Two therapeutic interventions were evaluated using MRI, vitamin A (all-trans retinol palmitate, RP), as a chemopreventative agent and the anti-angiogenic drug SU-5416. RP was found to significantly delay the time to first tumor observation by one month (P = 0.05). No differences in rates of tumor formation or growth rates were observed between control and RP-treated groups. MRI studies of rats treated with SU-5416 resulted in reduction in tumor growth rates compared to matched controls. These results show that MRI can be used to provide novel information relating to the therapeutic efficacy of agents against the ENU-induced tumor model.",
keywords = "ENU, Gliomas, Magnetic resonance imaging, N-ethyl-N-nitro sourea, Transplacental induction",
author = "Kish, {P. E.} and M. Blaivas and M. Strawderman and Muraszko, {K. M.} and Ross, {Donald (Don)} and Ross, {B. D.} and G. McMahon",
year = "2001",
doi = "10.1023/A:1012222522359",
language = "English (US)",
volume = "53",
pages = "243--257",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Magnetic resonance imaging of ethyl-nitrosourea-induced rat gliomas

T2 - A model for experimental therapeutics of low-grade gliomas

AU - Kish, P. E.

AU - Blaivas, M.

AU - Strawderman, M.

AU - Muraszko, K. M.

AU - Ross, Donald (Don)

AU - Ross, B. D.

AU - McMahon, G.

PY - 2001

Y1 - 2001

N2 - Human low-grade gliomas represent a population of brain tumors that remain a therapeutic challenge. Preclinical evaluation of agents, to test their preventive or therapeutic efficacy in these tumors, requires the use of animal models. Spontaneous gliomas develop in models of chemically induced carcinogenesis, such as in the transplacental N-ethyl-N-nitrosourea (ENU) rat model. However, without the ability to detect initial tumor formation, multiplicity or to measure growth rates, it is difficult to test compounds for their interventional or preventional capabilities. In this study Fisher-334 rats, treated transplacentally with ENU, underwent magnetic resonance imaging (MRI) examination in order to evaluate this approach for detection of tumor formation and growth. ENU-induced intracranial cerebral tumors were first observable in T2-weighted images beginning at 4 months of age and grew with a mean doubling time of 0.487 ± 0.112 months. These tumors were found histologically to be predominately mixed gliomas. Two therapeutic interventions were evaluated using MRI, vitamin A (all-trans retinol palmitate, RP), as a chemopreventative agent and the anti-angiogenic drug SU-5416. RP was found to significantly delay the time to first tumor observation by one month (P = 0.05). No differences in rates of tumor formation or growth rates were observed between control and RP-treated groups. MRI studies of rats treated with SU-5416 resulted in reduction in tumor growth rates compared to matched controls. These results show that MRI can be used to provide novel information relating to the therapeutic efficacy of agents against the ENU-induced tumor model.

AB - Human low-grade gliomas represent a population of brain tumors that remain a therapeutic challenge. Preclinical evaluation of agents, to test their preventive or therapeutic efficacy in these tumors, requires the use of animal models. Spontaneous gliomas develop in models of chemically induced carcinogenesis, such as in the transplacental N-ethyl-N-nitrosourea (ENU) rat model. However, without the ability to detect initial tumor formation, multiplicity or to measure growth rates, it is difficult to test compounds for their interventional or preventional capabilities. In this study Fisher-334 rats, treated transplacentally with ENU, underwent magnetic resonance imaging (MRI) examination in order to evaluate this approach for detection of tumor formation and growth. ENU-induced intracranial cerebral tumors were first observable in T2-weighted images beginning at 4 months of age and grew with a mean doubling time of 0.487 ± 0.112 months. These tumors were found histologically to be predominately mixed gliomas. Two therapeutic interventions were evaluated using MRI, vitamin A (all-trans retinol palmitate, RP), as a chemopreventative agent and the anti-angiogenic drug SU-5416. RP was found to significantly delay the time to first tumor observation by one month (P = 0.05). No differences in rates of tumor formation or growth rates were observed between control and RP-treated groups. MRI studies of rats treated with SU-5416 resulted in reduction in tumor growth rates compared to matched controls. These results show that MRI can be used to provide novel information relating to the therapeutic efficacy of agents against the ENU-induced tumor model.

KW - ENU

KW - Gliomas

KW - Magnetic resonance imaging

KW - N-ethyl-N-nitro sourea

KW - Transplacental induction

UR - http://www.scopus.com/inward/record.url?scp=0034756366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034756366&partnerID=8YFLogxK

U2 - 10.1023/A:1012222522359

DO - 10.1023/A:1012222522359

M3 - Article

C2 - 11718257

AN - SCOPUS:0034756366

VL - 53

SP - 243

EP - 257

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -